Jump to content



Recommended Posts

  • Replies 962
  • Created
  • Last Reply

Top Posters In This Topic

Top Posters In This Topic

Posted Images

In reply to: joyful on Wednesday 15/06/05 07:11pm

do they ever!!!


they have both the hpv vaccines mentioned below- they will receive royalties from both gsk and merck.


suggest you read pages 1 and 2 here

Link to comment
Share on other sites

party poopers:


GSJBW Cautious On CSL's HPV Vaccine


Tuesday, June 14, 2005 7:34:44 PM ET

Dow Jones Newswires


0930 [Dow Jones] STOCK CALL: Goldman Sachs JBWere says newsflow on CSL's (CSL.AU) HPV vaccine likely to be positive in near term as nears potential FDA filing later this year, but warns forecasts for rapid ramp up profile for HPV earnings have potential to disappoint. Also notes government approvals may take some time to obtain. GSJBW's DCF valuation on CSL of A$27 includes A$3 for HPV. Broker adds potential value of HPV to CSL largely captured in current share price. Maintains short-term Underperform rating. CSL last A$32.19. (RJN)





Link to comment
Share on other sites


New CSL facility a boon for biotechs

Helen Matterson

June 17, 2005


CSL is to build a $7 million facility in Melbourne to formulate biotechnology drugs for its own business and the biotech industry.


Biotechnology is a major focus for the research and development arm of the group, better known for its blood plasma products.


About a quarter of CSL's annual $150 million R&D budget is spent on biotechnology projects, and this is set to increase.


Initiatives to date include a vaccine against human papillomavirus which it licensed to pharmaceutical giant Merck & Co, the development of a reconstituted high-density lipoprotein to prevent secondary heart attacks, and the use of adjuvant technology to stimulate the immune system and provide a platform for vaccines.


Details of the facility will be announced at BIO 2005, the world's largest biotech convention, in Philadelphia next week by Victorian Premier Steve Bracks.








The Victorian Government is providing $2.7 million in funding.


The dual-function facility provides a means by which small biotech companies and academic groups can "formulate" early-state protein-based biotechnology drugs at cost.


Formulation is a crucial stage in which compounds are turned into a form which can be used in human clinical trials.


Typically this is done offshore in the US or Europe, and can be a great expense for start-up companies.


CSL chief scientific officer Andrew Cuthbertson said there were several tangible benefits for CSL.


These included potential collaborations between CSL and fledging biotechs or scientists that might lead to licensing deals in the future.


From a financial perspective the initiative would not be "profit-making" but neither would it run at a loss, Dr Cuthbertson said.


Originally CSL had planned to build just one facility for its own use, after finding it difficult to schedule formulation at its offshore facilities or to do this on a small scale.


Numerous approaches from the biotech industry had prompted it to take up the issue with the Victorian Government.


The dual facility, which should be up and running within two years, will also be a training ground for Swinburne University biotech students.


CSL shares fell 61c to $31.84.






Link to comment
Share on other sites

In reply to: drrc on Friday 17/06/05 07:16am

CSL takes a jab at global contention

Author: Eli Greenblat

Date: 20/06/2005

Words: 874

Source: AFR

Publication: The Financial Review

Section: Companies and Markets

Page: 15



If successful, CSL's latest vaccine could make the company famous internationally and very rich, writes Eli Greenblat.

CSL chief executive Brian McNamee is increasingly confident his company's human papillomavirus vaccine could grab global sales of $US2 billion ($2.6 billion) a year and replace the hepatitis B shot as the most widely used vaccine in the world.


The claim could gain more currency among investors in the second half of 2005 when CSL's partner in the HPV vaccine, Merck, approaches US health officials for final clearance.


A successful launch next year of the vaccine for HPV a common virus that can cause cervical cancer could add as much as $6 a share to the CSL stock price and deliver pre-tax profits from royalty payments of up to $200 million a year, some analysts believe.




Link to comment
Share on other sites


can u believe it.


i was playing with PRE = it went down =(

i was buying puts on CSL = the BARST@#D broke its 200day sma and is currently trending up, argh lucky i only bought 2 contracts ( 1800 cash) mmm i guess the good news is.. i can start buying Calls once it hits support... mmm odds odds odds.


but yes.. i did one thing right. buying CUE's.. thank god..


GOOOOO CSL! haha down to support so i can grab a few calls, then back up to $10000000 p/s *wink*


Link to comment
Share on other sites

Buyback news pumps up CSL

Trevor Chappell and Bruce Brammall



SHARES in blood products supplier CSL soared yesterday after the company announced a new buyback and restated its annual net profit target would be between $270 million and $295 million.


CSL, which also develops vaccines, will buy back up to eight million shares in the 12 months from July 12, 2005.


The company has about 189 million shares on issue.


The news sent CSL stocks surging $1.95, or 5.97 per cent, to $34.59 yesterday.







It is now about 3.5 per cent shy of its year high of $35.85 set in March.


On yesterday's closing price, the buyback, of more than 4 per cent of the company's stock, is valued at more than $276 million.


Citigroup Smith Barney analyst Rosemary Cummins said the announcement from CSL gave investors more confidence in the stock after some varying assessments from brokers.


A new share buyback had been expected, but not this soon.


"That's affirmation that they (CSL) think things are pretty good," Ms Cummins said.


In February this year, CSL announced a share buyback of up to 10 million shares or 5 per cent of issued capital.


CSL managing director Brian McNamee said the second buyback was underpinned by the company's "strong cash flows and balance sheet position".


"We are committed to managing the company's capital structure to the best advantage of our shareholders, which includes retaining a prudent level of gearing," Dr McNamee said.


"The buyback will improve investment return ratios such as earnings per share and return on equity and all shareholders will benefit."


He said that at the end of this latest buyback, CSL would have returned $550 million to shareholders ÃÆâ€â„¢ÃƒÆ’ƒâہ¡ÃƒÆ’‚¢ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â€š¬Ã…¡Ãƒâ€šÃ‚¬ÃƒÆ’…¡Ãƒâہ¡ÃƒÆ’‚¬ÃƒÆ’¢Ã¢Ã¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã‚¡ÃƒÆ’‚¬Ãƒâ€Â¦ÃƒÆ’¢Ã¢Ã¢â‚¬Å¡Ã‚¬Ãƒâ€¦Ã¢â‚¬Å“ more than the sum raised to acquire the global plasma therapeutics business of Aventis Behring in December 2003.


"At the same time the market value of CSL has more than doubled since making the announcement to acquire the business."


CSL reaffirmed a profit outlook statement made in April that net profit for 2004-05 would be between $270 million and $295 million.


The company said reaching the upper end of the profit range would depend on selling more of a large inventory acquired during the Aventis Behring deal.


The forecast net profit is also subject to currency fluctuations and material movements in the price of core plasma products.


The full-year net profit forecast does not include the profit from the sale of CSL's cell culture reagent business JRH Biosciences to US-based Sigma-Aldrich for $US370 million ($A492 million) in January this year.





Link to comment
Share on other sites

Ferret's Stock to Watch: CSL LIMITED


08:50, Wednesday, 29 June 2005



Sydney - Wednesday - June 29: (RWE Aust Business News)




CSL Ltd (CSL) has been a fantastic stock, originating from part

of the CSIRO back in the 1990s.

When the company was listed in 1994 hardly anybody wanted to know

The stock has been a Ferret favourite for years and yesterday

justified shareholders' faith in the company, reaffirming its April 15

outlook statement that annual net profit would be $270 to $295 million.

Investors should not be put off by big share prices, provided the

value is in the company.

CSL has an important place in the medical world and produces

products to enhance and improve the health of the people.

It is a world renowned developer, manufacturer and distributor of

human plasma, vaccine, pharmaceutical and diagnostic products.

What's also given shareholders a boost of confidence is that CSL

intends a further on-market buyback of up to eight million shares over

the 12 months beginning on July 12.

This is a virtually back-to-back operation, having just completed

another buyback in May.

Managing director Dr Brian McNamee said in yesterday's statement

that it was very likely that CSL will have returned to shareholders in

excess of the $550 million raised to acquire the global plasma

therapeutics business of Aventis Behring last year.

At the same time, the market value of CSL has more than doubled

since the company made the announcement to acquire the business.



Shares of CSL sold $1.66 higher at $34.29 yesterday. Rolling high

for the year has been $35.85 and low $21.75. Dividend is 43c a share to

yield a thin 1.25 per cent.

Earnings per share is 188.9c while P/E is a solid 18.18. Interim

dividend rose 5c to 17c fully franked.

The interim result, as expected, was a profit showing a rise of

531 per cent to $160 million on revenue which jumped 122.3 per cent to

$1.4 billion.

The result was driven by the inclusion of Aventis Behring,

acquired on March 31 2004, the realisation of a profit on discounted

inventory that came with the acquisition and an improvement in market


The result was inflated by a $96 million profit from realisation

of discounted inventory, although partly offset by a currency impact of

$24 million vs the Swiss franc and $10 million vs the US dollar.

CSL has advised that profit forecast adjustment for the full 2006

year due to tax expense would increase by $35-$45 million due to a change

in accounting for the unrealised portion of inventory profits with the

transition to Australian international financial reporting standards.

However, the cash tax paid will not change.

This will result in a 10 per cent reported profit downgrade.

CSL has confirmed guidance of a net profit for 2005 towards the

upper end of a $270-$295 million range, dependent on realising an

increased profit of around $150 million on inventory acquired at a

discount from the Aventis Behring acquisition, stable currency and plasma

prices and excluding a one-off profit from sale of JRH Biosciences.

But CSL is not without it critics, with Shaw Stockbroking

pointing to a lower level of inventory sales in 2006, flat sales from a

reduction in plasma throughput and the tax effect for its expectation of

a flat result.

With the extended valuation premium on CSL and some uncertainty

going forward, Shaw said it sees better value elsewhere in healthcare.

It maintains a target of $33.30.

Shaw didn't take into account the buybacks, including the one

announced yesterday.

However, CSL's share price has well and truly passed the broker's

target level set on a different wave length.



CSL Ltd is a global, specialty biopharmaceutical company that

develops, manufactures and markets products to treat and prevent serious

human medical conditions.

Innovation and new product development for unmet medical needs

continue to drive CSL's growth.

Headquartered in Melbourne, the CSL Group includes CSL Bioplasma,

CSL Pharmaceutical and ZLB Behring incorporating ZLB Plasma Services.

With major facilities in Australia, Germany, Switzerland, US and

Japan, CSL has over 7,000 employees working in 25 countries.

The company's products cover immunoglobulins to treat infections,

autoimmune diseases and for preventing haemolytic disease in the newborn;

plasma volume expanders to treat acute blood loss and severe burns;

clotting factors to treat bleeding disorders.

CSL also produces paediatric and adult vaccines; treatments for

infections and severe pain; products for skin disorders; new product

development and product life cycle improvement through global innovation

and academic collaboration.

Link to comment
Share on other sites

  • 2 weeks later...

CSL Albumin Prices To Rise - Citigroup


Thursday, July 07, 2005 8:20:15 PM ET

Dow Jones Newswires


1014 [Dow Jones] STOCK CALL: Citigroup Smith Barney expects prices for one of CSL's (CSL.AU) key products, albumin, to rise over next 12 months in distinct positive turnaround. Notes U.S. FDA has reversed a study cautious on albumin; adds there have been several other positive developments on supply side, such as reduction in U.S., China plasma collection. Keeps Buy rating, A$42.20 price target vs latest down 0.5% at A$33.79.





Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now

  • Create New...